Characterization of Chronic Hand Eczema

Official title

Pathophysiological Characterization of Chronic Hand Eczema Subtypes and Atopic Dermatitis With Noninvasive Molecular and Imaging Techniques in Subjects With Moderate to Severe Chronic Hand Eczema, Subjects With Atopic Dermatitis, and Healthy Volunteers

Overview

Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.

Detailed description

Prospective longitudinal study of adult patients with moderate to severe chronic hand eczema, subject with modreate to severe Atopic Dermatitis and healthy volenteers to assess changes in morphological parameters and molecular signatures with non-invasive techniques.In addition, disease severity and their association with occupation, smoking status, quality of life will be evaluated per CHE subtypes and compared to subjects with only AD. Samples and data collected from healthy volunteers will be used as controls in the analyses.

Interventions

• Genetic Tape stripping
  Optional genetic analysis for chronic hand eczema

Primary outcome measures

• Characterize differences in skin morphological parameters [Time frame: 12 months]
• Characterize differences in skin molecular signature [Time frame: 12 months]

Secondary outcome measures (3)

• Determine disease severity impact on lifestyle [Time frame: 12 months]
• Determine disease severity impact on quality of life [Time frame: 12 months]
• To biobank plasma, serum, whole blood, DNA (buffy coat), stool, skin surface material and skin tissue. [Time frame: 10 years]

Eligibility criteria

Inclusion criteria

All subjects:

• Male or female subjects aged 18 to 65 years, inclusive, at the time of consent.
• Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
• Subject must be willing to comply with all study procedures and must be available for the duration of the study.

CHE subjects only:

• Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).
• Subject has moderate to severe CHE as defined by an IGA score of ≥3 at Screening and Day 1.
• Subject has CHE covering ≥0.25% of BSA on palmar surface of hands at Screening and Day 1.
• Subjects has CHE that can be categorized in one of the following CHE subtypes at Day 1:

• Atopic hand eczema (without wet-work or excessive contact with irritants)
• Irritant contact hand eczema without atopic disease
• Hyperkeratotic hand eczema without atopic disease
• Vesicular hand dermatitis without atopic disease
• Allergic contact hand eczema without atopic disease
• Idiopathic hand eczema without wet-work, excessive contact with irritants, atopic disease, hyperkeratotic morphology, allergic contact hand eczema and vesicular hand eczema.

Subjects with only AD:

• Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
• Subject has at least a 6-month history of AD and had no significant flares in AD for at least 4 weeks before Screening (information obtained from medical chart or subject's physician, or directly from the subject).
• Subject has moderate to severe AD as defined by a vIGA-AD score of ≥3 at Screening and Day 1.
• Subject has AD covering ≥0.5% of BSA at Screening and Day 1.
• Subject has an AD lesion covering ≥0.25% of BSA on the forearm at Screening and Day 1.Healthy Volunteers only:
• Subject is in good general health, according to the investigator's judgment based on medical history and physical examination.

Exclusion criteria

All subjects:

• Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
• Subject has used systemic antibiotics within 2 weeks prior to Day 1.
• Subject has used topical antibiotics within 1 week prior to Day 1.
• Subject has used topical products containing urea or salicylic acid within 1 week prior to Day 1.
• Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
• Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.
• Subject has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1. Use of sunscreen products are recommended when exposure cannot be avoided.
• Subject is a female who is pregnant or who is planning to become pregnant during the study.

CHE subjects only:

• Subject has clinically infected chronic hand eczema on hands and/or wrists.
• Subject with suspected or proven hand eczema protein contact dermatitis.
• Subject has used doxepin within 1 week prior to Day 1.
• Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
• Subject has used any topical medicated treatment that could affect CHE within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, topical retinoids, crisaborole, calcineurin inhibitors, tars, antimicrobials, medical devices, and bleach baths.
• Subject has used alitretinoin, isotretinoin, acitretin or other systemic retinoids within 4 weeks before Day 1, or has not completely recovered from its side effects.
• Subject has used systemic treatments (other than biologics) that could have an impact on CHE less than 4 weeks prior to Day 1 (eg, calcineurin inhibitors, methotrexate, cyclosporin, hydroxycarbamide \[hydroxyurea\], azathioprine), or systemic steroids (including oral or injectable corticosteroids).

Note: Intranasal corticosteroids, eye or ear drops containing corticosteroids, and inhaled corticosteroids for stable medical conditions are allowed.

• Subject has used dupilumab within 12 weeks prior to Day 1.
• Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
• Subject has had psoralen-UV-A (PUVA) treatment within 4 weeks prior to Day 1.

Subjects with only AD:

• Subject has clinically infected AD.
• Subject has AD lesion on hand and/or feet at screening or Day 1.
• Subject has received an intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Day 1.
• Subject has used doxepin within 1 week prior to Day 1.
• Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day 1.
• Subject has used any topical, medicated treatment that could affect AD within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole, calcineurin inhibitors, ruxolitinib, tars, antimicrobials, medical devices, and bleach baths.
• Subject has used systemic treatments (other than biologics) that could affect AD less than 4 weeks prior to Day 1, including, but not limited to, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine, oral/injectable corticosteroids, baricitinib, upadacitinib, and abrocitinib.
• Subject has used dupilumab within 12 weeks prior to Day 1.
• Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
• Subject has had PUVA treatment within 4 weeks prior to Day 1. Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are allowed.
• Subject has used tralokinumab within 12 weeks prior to Day 1.

Healthy Volunteers only:

• Subject has history of atopic dermatitis, allergic rhinitis, or asthma.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model

Cohort

Study locations

Canada · 1 center

• Innovaderm Research — Montreal

Identifiers

NCT: NCT05026554 · INNO-5024

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗